STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR): The University Hospital of Manchester, England, is now the first clinic outside Sweden to have used the STEEN Solution™ method clinically. Two double lung transplantations have been performed with positive results. “It is exciting to note that Steen Solution™ and lung evaluation outside the body are beginning to become clinical practice in a leading country such as the UK, and that more people with lung disease thereby receive effective treatment,” says Magnus Nilsson, CEO of Vitrolife.
